Abstract
Neo-Family History Score is a Novel Biomarker of Pathological Complete Response, Safety, and Survival Outcomes in Patients with Breast Cancer Receiving Neoadjuvant Platinum-Based Chemotherapy: A Retrospective Analysis of Two Prospective Trials
Highlights
Homologous recombination repair gene mutations are associated with increased platinumbased chemosensitivity, whereas few studies have reported the predictive value of family history of cancer for breast cancer in the neoadjuvant setting
Our study revealed that Neo-Family History Score (NeoFHS) is a practical and effective biomarker for predicting pathological complete response (pCR) and survival outcomes and chemotherapy-induced Adverse events (AEs) for neoadjuvant platinum-based chemotherapy for breast cancer
Logistic regression analyses were used to derive odds ratios (ORs) with 95% confidence intervals (CIs) when we evaluated the correlations of pCR with family history scores and baseline information [age, clinical tumor (T) stage, clinical nodal status, Hormone receptor (HorR) status, human epidermal growth factor receptor 2 (HER2) status, Ki67 index, and Body mass index (BMI)], and the potential interactions between NeoFHS and clinicopathological features for pCR
Summary
Homologous recombination repair gene mutations are associated with increased platinumbased chemosensitivity, whereas few studies have reported the predictive value of family history of cancer for breast cancer in the neoadjuvant setting. This study aimed to construct a brief and effective novel family history scoring system and explore its association with pathological complete response (pCR), survival outcomes, and safety for locally advanced breast cancer receiving platinum-based neoadjuvant chemotherapy. Cisplatin-based chemotherapy could induce superior response in locally advanced breast cancer.[5,6,7,8] Our prior research showed that patients with locally advanced breast cancer achieved an encouraging pCR rate (34.4%) after receiving neoadjuvant cisplatin plus paclitaxel. To well distinguish those who respond from those who do not in the neoadjuvant setting, research is warranted to investigate the potential biomarkers for individual chemosensitivity at the initial diagnosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
